Literature DB >> 22192652

Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.

Beate Schultheis1, Henrike Neumann, Renée Roy, Vera Heuer, Gerhard Kummer, Dirk Strumberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22192652     DOI： 10.5414/cpp50072

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  2 in total

1.  Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors.

Authors:  E Gabriela Chiorean; Susan M Perkins; R Matthew Strother; Anne Younger; Jennifer M Funke; Safi G Shahda; Noah M Hahn; Kumar Sandrasegaran; David R Jones; Todd C Skaar; Bryan P Schneider; Christopher J Sweeney; Daniela E Matei
Journal:  Mol Cancer Ther       Date:  2020-08-26       Impact factor: 6.261

2.  Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.

Authors:  Yi Zhu; Xiaochen Zhang; Xiaoe Lou; Min Chen; Peihua Luo; Qiaojun He
Journal:  Clin Exp Pharmacol Physiol       Date:  2018-04-25       Impact factor: 2.557
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.